Abstracts Archive - Page 881 of 2607 - ACR Meeting Abstracts

Abstract Number: 0669 • ACR Convergence 2020
Calcium Pyrophosphate Crystal Deposition in Gouty Tophi
Hang-Korng Ea¹, Alan Gauffenic², Quand Nguyen³, Nhu Pham³, Oceane Olivier², Vincent Frochot⁴, Dominique Bazin⁵, Nghia Le³, Caroline Marty², Agnès Ostertag², Martine Cohen-Solal¹, Jean-Denis Laredo⁶, Pascal Richette⁷ and Thomas Bardin⁸, ¹Université de Paris, INSERM UMR 1132, BIOSCAR, AP-HP, DMU Locomoteur, Paris, France, ²Université de Paris, INSERM UMR 1132, BIOSCAR, Paris, France, ³Vien Gut Medical Center and French-Vietnamese research center on gout and chronic diseases, Ho Chi Ming, Vietnam, ⁴Hôpital Tenon, Service des explorations fonctionnelles multidisciplinaires, Sorbonne université, UMR_S1155, Paris, France, ⁵Institut de Chimie Physique, Université Paris-Saclay et CNRS - UMR8000, Orsay, France, ⁶AP-HP Université de Paris, Paris, ⁷Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, ⁸Université de Paris, INSERM U1132 and Hôpital Lariboisièe, Paris, France, Paris, France
Background/Purpose: The coexistence of calcium pyrophosphate (CPP) and monosodium urate crystals is rarely reported in gouty tophi. We investigated CPP crystal deposits in a series…
Abstract Number: 0670 • ACR Convergence 2020
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
Sara Tedeschi¹, Kazuki Yoshida¹, Weixing Huang² and Daniel H. Solomon¹, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Prior studies of calcium pyrophosphate crystal deposition disease (CPPD) epidemiology either focused on the entire spectrum of CPPD or identified patients with its acute…
Abstract Number: 0671 • ACR Convergence 2020
Structured Cardiovascular Assessment in Gout Incorporating Carotid Ultrasound: Analysis of Subsequent Events in the Follow-Up
Mar Monzó¹, Neus Quilis², Laura Ranieri², Alejandro San-Martín³ and Mariano Andrés⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital Universitario del Vinalopó, Alicante, Spain, ³Clínica HLA Vistahermosa, Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain
Background/Purpose: Gout is an independent cardiovascular (CV) risk factor. This excess of morbidity and mortality requires optimal management, especially in high-risk individuals. Therefore, the inclusion…
Abstract Number: 0672 • ACR Convergence 2020
Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares
Natalie McCormick¹, Chio Yokose¹, Clara Chen², Tuhina Neogi³, David Hunter⁴, Hyon Choi⁵ and Yuqing Zhang⁶, ¹Massachusetts General Hospital, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston
Background/Purpose: Cross-sectional radiologic evidence suggests monosodium urate crystal deposition among gout patients is a symmetrical phenomenon,1 but no study has examined the longitudinal patterns in…
Abstract Number: 0673 • ACR Convergence 2020
Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure
Brian LaMoreaux¹, Megan Francis-Sedlak¹, Scott Neville² and Robert Holt¹, ¹Horizon Therapeutics plc, Lake Forest, IL, ²Foot and Ankle Center, Mooresville, IN
Background/Purpose: Gout can cause uric acid deposition in joints, soft tissues, and organs (1) and is associated with heart disease, kidney disease, hypertension, hyperlipidemia, diabetes,…
Abstract Number: 0674 • ACR Convergence 2020
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
Ruriko Koto¹, Akihiro Nakajima¹, Hideki Horiuchi¹ and Hisashi Yamanaka², ¹Teijin Pharma Limited, Tokyo, Japan, ²Sanno Medical Center, Tokyo, Japan
Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…
Abstract Number: 0675 • ACR Convergence 2020
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers
Zancong Shen¹, Elizabeth Polvent², Vijay Hingorani², Andrea Clouser-Roche², Chris Mikelatis², Rongzi Yan², Shunqi Yan² and Li-Tain Yeh², ¹Arthrosi therapeutics, Laguna Hills, CA, ²Arthrosi Therapeutics Inc, Laguna Hills, CA
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. AR882 exhibited linear…
Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Joshua Gavin¹, Yashswee KC², Evan Dombrosky³, Nehal Shah⁴ and Youssef Roman⁴, ¹Virginia Commonwealth University School of Medicine, Richmond, ²Virginia Commonwealth University School of Medicine, Henrico, VA, ³Virginia Commonwealth University School of Medicine, Glen Allen, VA, ⁴Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…
Abstract Number: 0677 • ACR Convergence 2020
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
John Botson¹, Paul Peloso², Katie Obermeyer³, Brian LaMoreaux³, Lin Zhao³, Michael Weinblatt⁴ and Jeff Peterson⁵, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Horizon Therapeutics plc, Gurnee, IL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Western Washington Medical Group Arthritis Clinic, Bothell, WA
Background/Purpose: Consistent, though limited, published data suggests that methotrexate (MTX) improves treatment response in patients treated with pegloticase for uncontrolled (refractory) gout. Recent case series1-3…
Abstract Number: 0678 • ACR Convergence 2020
Patient Characteristics and Patterns of Urate-lowering Treatments in Older Patients with Incident Gout
Kazuki Yoshida¹, Jun Liu², Daniel H Solomon³ and Seoyoung Kim³, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout is a common inflammatory arthritis caused by monosodium urate crystal deposition in the joints. Despite this well-understood pathophysiologic mechanism of disease and ACR and EULAR…
Abstract Number: 0679 • ACR Convergence 2020
Epidemiology of Intra-Articular Mineralization on Knee Dual-Energy Computed Tomography: The Multicenter Osteoarthritis Study
Mohamed Jarraya¹, Tuhina Neogi², John Lynch³, David Felson², Piran Aliabadi⁴, Michael Nevitt³, Cora Lewis⁵, James Torner⁶ and Ali Guermazi², ¹Boston University School of Medicine, Boston, ²Boston University School of Medicine, Boston, MA, ³University of California at San Francisco, San Francisco, ⁴Brigham and Womens Hospital, Boston, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶University of Iowa, Iowa City, IA
Background/Purpose: Computed tomography (CT) has a higher sensitivity for the detection of intraarticular mineralization in comparison with commonly used imaging techniques in knee osteoarthritis (OA)…
Abstract Number: 0680 • ACR Convergence 2020
Sustained Treat to Target Uric Acid Lowering Therapy Markedly Lowers Fatty Acids Levels in Gout Patients
Monica Guma¹, Roxana Coras², Ru Liu-Bryan³ and Robert Terkeltaub⁴, ¹Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³Department of Medicine, VAMC/University of California San Diego, San Diego, ⁴VA Medical Center/UC San Diego, San Diego, CA
Background/Purpose: Though hyperuricemia is implicated in cardiovascular disease, the metabolic syndrome, and type 2 diabetes in both gout and in asymptomatic patients, the core metabolism…
Abstract Number: 0681 • ACR Convergence 2020
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Michael Toprover¹, Michael Mechlin², Anastasia Slobodnick³, Virginia Pike⁴, Cheongeun Oh⁵, Claudine Davis², Theodore Fields⁶, Fabio Becce⁷ and Michael Pillinger⁸, ¹New York University Langone Health, New York, NY, ²NYU Langone Health, New York, NY, ³Stamford Health Medical Group, Stamford, CT, ⁴NYU Langone Health, Brooklyn, NY, ⁵NYU Grossman School of Medicine, New York, ⁶Hospital for Special Surgery, New York, NY, ⁷Lausanne University, Lausanne, Switzerland, ⁸New York University Grossman School of Medicine, New York,, NY
Background/Purpose: Spinal gout is reported as a rare event, presenting as acute back pain, neuropathy, and spinal compression. Diagnosis is commonly based on identification of…
Abstract Number: 0682 • ACR Convergence 2020
Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout
Fatima Alduraibi¹, Karina Ricart¹, Rakesh Patel¹, Alexander Szalai¹, Joshua Melnick² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Vestavia Hills, AL
Background/Purpose: To understand the role of inflammatory cytokines and oxidative stress biomarkers in the renal disease in people with gout. We hypothesized that higher gout…
Abstract Number: 0683 • ACR Convergence 2020
Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate
Yang Song¹, Yan Xin¹, Michael Weinblatt², Jason Chamberlain¹, Katie Obermeyer³, Lin Zhao³, Colleen Canavan³, Paul Peloso⁴ and Srini Ramanathan¹, ¹Horizon Therapeutics plc, South San Francisco, CA, ²Brigham and Women's Hospital, Boston, MA, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴Horizon Therapeutics plc, Gurnee, IL
Background/Purpose: In an open-label trial in adult patients with uncontrolled gout (MIRROR open-label [OL] trial) evaluating pegloticase co-treatment with methotrexate (MTX), 78.6% patients maintained serum…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].